LEXICON
No.131 May 17, 2013

Roadmap to further promote the use of generics
後発医薬品のさらなる使用促進のためのロードマップ
Generic, generic drug
後発医薬品
Biosimilar, follow-on biologics
バイオシミラー、バイオ後続品

Generics or generic drugs (後発医薬品) are defined by the Ministry of Health, Labor and Welfare (MHLW) as drugs that are identical to (same as) the original drugs (先発医薬品) in terms of the active pharmaceutical ingredients (APIs; 有効成分), administration route (投与経路),...

To read the full story

LEXICON

By Philip Carrigan

The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…

By Shinya Sato

Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…